secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001437749-25-016131
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed posts Q1 net loss $4.9M, secures $50M ATM facility; reports positive Phase 2b DLB results
--------------------------------------------------------------------------------

- Entered $50M at-the-market offering agreement with Leerink Partners; 3% commission on sales.
- Cash and marketable securities $35.2M at March 31, 2025, down from $38.9M at Dec 31, 2024; runway into mid-2026.
- Net loss $4.9M for Q1 2025 compared to $2.5M in Q1 2024, driven by higher R&D costs for neflamapimod.
- Sixteen-week extension data from RewinD-LB Phase 2b showed CDR-SB improvement (p<0.001 vs old capsules, p=0.003 vs placebo); Phase 3 planned in mid-2026.
- Initiating Phase 2a trials in primary progressive aphasia (mid-2025) and ischemic stroke recovery (recently started).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774925016131/0001437749-25-016131-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774925016131/crvo20250509_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-016131

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer